Abstract:Recent advances in the fields of thromboinflammation and immunothrombosis induced a paradigm shift integrating platelets as key components of the immune system, independent of their hemostatic functions. Platelets constitutively express a plethora of immune receptors such as toll-like receptors (TLRs), complement receptors, antibody receptors (FcR), and intracellular NOD-like receptors (NLRs) and, upon activation, can also upregulate and secrete an arsenal of immunomodulatory molecules, regulating both the innate and adaptive immune responses [<a href="#">1</a>,<a href="#">2</a>]. Although platelets were initially shown to promote a proinflammatory and prothrombotic state in sterile and infectious injuries, recent studies have shown protective roles for platelets during inflammation, in particular in the maintenance of vascular integrity, resolution of inflammation, and promotion of tissue repair [<a href="#">3</a>,<a href="#">4</a>]. More recently, platelet microvesicles have emerged as novel regulators of thrombo-inflammatory diseases, which, unto themselves, can regulate both innate and adaptive immunity [<a href="#">5</a>,<a href="#">6</a>]. Inflammatory/immune alteration of platelet function does not occur solely in periphery, but might also result from transcriptional and translational alteration in the genetic profile of megakaryocytes. The pro- or anti-inflammatory functions of platelets are highly dynamic with distinct receptors engaged in different vascular beds during the course of the inflammatory response. Likewise, the composition and structure of thrombi under inflammatory conditions is highly heterogeneous, dictated directly by the specific nature of the insult and the characteristics of the target vascular bed/organ. Moreover, recent studies have shown significant changes in the composition of the thrombi within the same organ during disease progression, increasing the complexity of successful treatment under thromboinflammatory conditions without global alteration of the hemostatic balance. Therefore, the success of novel anti-thrombotic drugs or the strategic repurposing of existing therapies will need to be tailored to each stimulus, organ, and disease state in an effort to limit both thrombosis and inflammation while simultaneously preserving vascular integrity and organ function.

Inhibition of Platelet Activation by Clopidogrel Prevents Hypertension-Induced Cardiac Inflammation and Fibrosis

Systemic Evaluation of Platelet and Leukocyte Activation and Interaction in A Rat Model of Pulmonary Arterial Hypertension

Inhibition of Farnesyl Pyrophosphate Synthase Prevents Norepinephrine–induced Fibrotic Responses in Vascular Smooth Muscle Cells from Spontaneously Hypertensive Rats

Modulation Of Platelet Activation And Thrombus Formation Using A Pan-Pi3k Inhibitor S14161

Clopidogrel reduces lipopolysaccharide-induced inflammation and neutrophil-platelet aggregates in an experimental endotoxemic model

Critical role of peroxisome proliferator-activated receptor a in promoting platelet hyperreactivity and thrombosis under hyperlipidemia

Platelets, a Key Cell in Inflammation and Atherosclerosis Progression

Abstract 4140979: CD34 + Cells Contributed to Cardiac Fibrosis Are Regulated by Hyperlipidemia

The Function and Regulation of Platelet P2Y12 Receptor

Lentivirus Mediated Il-17r Blockade Improves Diastolic Cardiac Function in Spontaneously Hypertensive Rats

PD-L1 Regulates Platelet Activation and Thrombosis via Caspase-3/GSDME Pathway

Platelet Microparticle-Derived MiR-320b Inhibits Hypertension with Atherosclerosis Development by Targeting ETFA

Platelet Internalization Mediates Ferroptosis in Myocardial Infarction

Buyang Huanwu decoction ameliorates myocardial injury and attenuates platelet activation by regulating the PI3 kinase/Rap1/integrin α(IIb)β(3) pathway

IL-37 Attenuates Platelet Activation and Thrombosis Through IL-1R8 Pathway

Human platelets express functional thymic stromal lymphopoietin receptors: a potential role in platelet activation in acute coronary syndrome

The Influence of the Anti-platelet Drugs on Platelet Activation of the Patients with Acute Cerebral Infarction

Inflammation modifies the platelet reactivity among thrombocytopenia patients undergoing percutaneous coronary intervention

Inhibition of profibrotic microRNA-21 affects platelets and their releasate

Platelets: bridging thrombosis and inflammation

Single‐Cell Spatial Transcriptomics Unveils Platelet‐Fueled Cycling Macrophages for Kidney Fibrosis